Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial (Q38001693)
Jump to navigation
Jump to search
scientific article published on 09 April 2012
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial |
scientific article published on 09 April 2012 |
Statements
1 reference
Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial (English)
1 reference
David Allsup
1 reference
Daniel Catovsky
1 reference
Claire E Dearden
1 reference
Estella Matutes
1 reference
Terry J Hamblin
1 reference
Andrew Rawstron
1 reference
David Oscier
1 reference
Andrew R Pettitt
1 reference
Melanie Oates
1 reference
George A Follows
1 reference
Richard Jackson
1 reference
Stacey Carruthers
1 reference
James Dodd
1 reference
Susanna Dodd
1 reference
Gillian G Johnson
1 reference
Anna Schuh
1 reference
Adrian Bloor
1 reference
Anton Kruger
1 reference
Julie Blundell
1 reference
Samir Agrawal
1 reference
Stephen Proctor
1 reference
Earnest Heartin
1 reference
9 April 2012
1 reference
1 reference
30
1 reference
14
1 reference
1647-1655
1 reference
Identifiers
1 reference
1 reference